The importance of RWE in SMA (Rare diseases) and the importance of registries
With the growing body of evidence and an evolving treatment landscape, the classification of subtypes needs a revision and Real-World Evidence becomes more and more important.
In this video you can hear Prof. Eugenio Mercuri's perspective on the current paradigm shift in SMA, the meaning of Real-World Evidence beyond clinical trials and why it is important to see the efficacy of a treatment in relation to natural history.
Prof. Eugenio Mercuri
Paediatric Neurology and Psychiatry Unit, Gemelli Hospital Catholic University Foundation, Rome, Italy
Eugenio Mercuri is Professor of Paediatric Neurology at the Catholic University, Rome, Italy, where he specialises in neonatal neurology and is the Director of the Department of women, children and public health sciences at Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Professor Mercuri received his medical degree from the University of Messina (Medicine and Surgery), and between 1987 and 1991 he specialised in paediatric neurology and child psychiatry. He completed his PhD in Developmental Neurosciences at the Catholic University, Rome, in 1995. He has currently authored or co-authored over 550 publications in the field of paediatric neurology.
Biogen-190999 november 2022
SMA type 3: Treated vs untreated (Pera et al 2021)
After the age of 7 there were significant difference between treated and untreated patients (mean 12-month change (SD) in HFMSE score:
8-14 years: 0,53 (3,31) vs -2,46 (4,55) p < 0,0001
15-19 years: 0,91 (5,19) vs -1,61 (3,75) p = 0,024
>20 years: 1,02 (3,47) vs -1,65 (3,42) p < 0,0001
Before the age of 7 years the difference did not reach significance.
The analysis of this data, should however be interpreted with caution due to clinical heterogeneity of SMA type 3 and number of variables such as wide age range, age of onset, functional status etc.
Tid: 11:06
Bild: Från filmen
Biogen-194281 december 2022
Senast uppdaterad: 2022-12-21
Se mer
CHOP-INTEND video instructions
Läs mer
Contains instructions on how to perform CHOP-INTEND and how to complete the test paper
HFMSE video instructions
Läs mer
Contains instructions on how to perform HFMSE and how to complete the test paper
RULM video instructions
Läs mer
Contains instructions on how to perform RULM and how to complete the test paper
Independent meta-analysis of treatment effect with nusinersen
Läs mer
In just a few minutes, this PubExplainer gives you an overview of the results of the independent meta-analysis performed by Coratti et al., on real world treatment effect with nusinersen.
Fatigable or not? That is the question in SMA
Läs mer
Dr. Bartels explains how to distinguish between perceived fatigue and fatigability and how the endurance shuttle tests can be used to assess fatigability across the SMA spectrum.
ATEND – an outcome measure developed for adult ”non-sitters” with SMA
Läs mer
Dr. Duong explains why a novel outcome measure is needed for adult non-sitters, how it was developed using a human-centered approach and her experience of using the ATEND both in clinic and remotely.
Outcome measures in adult SMA patients – a Canadian toolkit
Läs mer
Dr. Rodrigue reviews a Canadian outcome measure toolkit för adults with SMA. He discusses the needs unmet by the existing assessment scales and how digital assessments can be an important complement.
NURTURE-study: presymptomatic infants treated with nusinersen
Läs mer
This short PubExplainer gives you an overview of the results of the March 29, 2019 interim analysis of the NURTURE-study in presymptomatic infants treated with nusinersen by De Vivo et al.
Results from a German real world cohort study in adult SMA-patients
Läs mer
This PubExplainer, on a publication by Hagenacker et al., provides an overview of one of the largest and most diverse real-world studies in adult SMA-patients. The patients were followed at 10 centers in Germany.
Real-world data on adult SMA-patients from 18 Italian centers
Läs mer
This PubExplainer, by Maggi et al., provides an overview of one of the largest real-world studies in adult SMA-patients published so far. The patients were followed at 18 centers in Italy.
Discover the latest Real-World Evidence-SMA
Läs mer
A critical review and meta-analysis for more than 2600 SMA patients worldwide. To what extent can a treatment change the natural history outside of the clinical trial profile?
Presentation Habilitation and rehabilitation in spinal muscular atrophy
Watch more
This presentation was hosted by Anna-Karin Kroksmark during 2020's Listen & Learn meeting. It was a break-out session intended for physiotherapists on habilitation and rehabilitation in SMA.
Informationsfilm om hur Spinraza (nusinersen) administreras